ekso20251231_10ka.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 001-37854

Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or Other Jurisdiction of

Incorporation or Organization)

99-0367049

(I.R.S. Employer

Identification No.)

101 Glacier Point, Suite A

San Rafael, California 94901

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (510) 984-1761

Securities registered pursuant to section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	EKSO	Nasdaq Stock Market LLC
		(Nasdaq Capital Market)

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $8,158,292 based on the last sale price for such stock on June 30, 2025, the last business day of the registrant's most recently completed second fiscal quarter.

As of April 2, 2026, the registrant had 3,563,381 outstanding shares of common stock.

DOCUMENTS INCORPORATED BY REFERENCE:

None.

Explanatory Note		3
Part III
Item 10	Directors, Executive Officers and Corporate Governance	3
Item 11	Executive Compensation	7
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	11
Item 13	Certain Relationships and Related Transactions and Director Independence	13
Item 14	Principal Accountant Fees and Services	14
Part IV
Item 15	Exhibits, Financial Statements and Financial Statement Schedules	15
	Signatures	21

Name	Age	Position
*Directors*
Scott G. Davis	56	Chief Executive Officer and Director
Mary Ann Cloyd	71	Director
Corinna Lathan, Ph.D.	58	Director
Charles Li, Ph.D.	41	Director
Deborah Lafer Scher	67	Director
*Executive Officers (who are not also directors)*
Jerome Wong	52	Chief Financial Officer and Corporate Secretary
Jason C. Jones	54	Chief Operating Officer

	·	appointing, evaluating, retaining, approving the compensation of, and assessing the independence of our independent auditor;
	·	overseeing the work of our independent auditor, including through the receipt and consideration of certain reports from the independent auditor;
	·	reviewing and discussing with management and the independent auditors our annual and quarterly financial statements and related disclosures;
	·	monitoring our internal control over financial reporting, disclosure controls and procedures and the code of business conduct;
	·	discussing our risk management policies;
	·	establishing procedures for the receipt and retention of accounting related complaints and concerns;
	·	developing and reviewing policies and procedures for reviewing and approving or ratifying related person transactions;
	·	meeting independently with our internal audit staff, if any, independent auditors and management;
	·	preparing the Audit Committee Report required by SEC rules; and
	·	overseeing and reviewing the Company's cybersecurity, privacy and other information technology risks.

	·	reviewing and approving (or, when the Compensation Committee deems it appropriate, recommending for approval by our Board of Directors) the compensation of our executive officers, including the Chief Executive Officer and our other executive officers;
	·	reviewing and making recommendations to our Board of Directors with respect to incentive- compensation and equity-based plans that are subject to Board approval;
	·	approving tax-qualified, non-discriminatory employee benefit plans (and parallel nonqualified plans) for which stockholder approval is not sought and pursuant to which options or stock may be acquired by our officers, directors, employees or consultants;
	·	reviewing and making recommendations to our Board of Directors with respect to director compensation;
	·	reviewing and approving (or, when the Compensation Committee deems it appropriate, recommending for approval by our Board of Directors), the creation or revision of any clawback policy on the recoupment of incentive compensation; and
	·	overseeing and administering our equity incentive plans.

	·	identifying individuals qualified to become Board members;
	·	recommending to our Board of Directors the persons to be nominated for election as directors and to each of the committees of our Board of Directors;
	·	monitoring issues and developments related to matters of corporate governance; and
	·	recommending to our Board of Directors, where appropriate, changes in corporate governance principles and practices;

•	Scott G. Davis, our President and Chief Executive Officer;
•	Jerome Wong, our Chief Financial Officer and Corporate Secretary; and
•	Jason C. Jones, our Chief Operating Officer

Name and Principal Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)⁽¹⁾		Option Awards ($)⁽¹⁾		Non-Equity Incentive Plan Compensation ($)		All Other Compensation ($)⁽²⁾		Total ($)
Scott G. Davis	2025		425,000		63,750		420,000		—		—		—		908,750
President and Chief Executive Officer	2024		375,000		94,501		—		—		—		3,516		473,017
Jerome Wong	2025		325,000		48,750		102,375		—		—		15,500		491,625
Chief Financial Officer	2024		325,000		54,600		—		—		—		15,250		394,850
Jason C. Jones	2025		325,000		48,750		78,750		—		—		15,500		468,000
Chief Operating Officer	2024		325,000		54,600		—		—		—		15,250		394,850

		OPTION AWARDS					STOCK AWARDS
		Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Yet Vested (#)⁽¹⁾		Market Value of Shares or Units of Stock That Have Not Yet Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units, or Other Rights (#)⁽³⁾	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Yet Vested ($)
Scott G. Davis		—	—	—	—	—	—		—	185,000	1,598,400
Jerome Wong		155	—	—	267.75	8/28/2027	—		—	—	—
Jerome Wong		200	—	—	395.85	7/13/2028	—		—	—	—
Jerome Wong										40,000	345,600
Jason C. Jones		888	—	—	461.25	11/1/2028	—		—	—	—
Jason C. Jones		844	—	—	137.25	11/6/2029	—		—	—	—
Jason C. Jones		—	—	—	—	—	3,788	_⁽²⁾	32,728	—	—
Jason C. Jones		—	—	—	—	—	—		—	32,000	276,480
(1)	This restricted stock award vests in equal installments over three years on the anniversaries of the vesting commencement date.
(2)	Vesting commenced January 2, 2024.
(3)	This award of phantom performance RSUs is scheduled to vest upon (i) the occurrence of a "change in control," and (ii) achievement of a "stock price" of at least $7.50, in each case within the five-year period following the date of grant and subject to continued employment through the date of achievement (the "Phantom PSU Performance Conditions").

Name	Fees Earned or Paid in Cash ($)	Stock Awards ($)⁽¹⁾⁽²⁾	Total ($)
Mary Ann Cloyd	80,000	88,335	168,335
Corinna Lathan, Ph. D.	52,500	88,335	140,835
Charles Li, Ph. D.	52,500	88,335	140,835
Deborah Lafer Scher	45,000	88,335	133,335

Name	Options (#)	RSUs(#)
Mary Ann Cloyd	-	15,746
Corinna Lathan, Ph.D.	-	15,746
Charles Li, Ph.D.	14,334	15,746
Deborah Lafer Scher	-	15,746

	Member ($)	Chair ($)
Board of Directors	35,000	70,000
Audit Committee	7,500	15,000
Compensation Committee	5,000	10,000
Nominating and Governance Committee	5,000	10,000

Name of Beneficial Owner	Number of Shares of Common Stock	Percent of Common Stock	Number of Shares of Series B Preferred Stock	Percent of Series B Preferred Stock	Total Voting Power %
*5% Stockholders*
Armistice Capital, LLC⁽¹⁾	291,146	8.2%	—	—	6.8%
Cedar Holdings Mgmt LLC⁽²⁾	210,000	5.9%	—	—	4.9%
Daniel Asher⁽³⁾	435,432	12.2%	2,926	50%	18.5%
Hood River Capital Management LLC⁽⁴⁾	63,892	1.8%	2,926	50%	9.8%
*Directors*
Mary Ann Cloyd⁽⁵⁾	30,447	*	—	—	*
Scott G. Davis ⁽⁶⁾	78,952	2.2%	—	—	1.9%
Corinna Lathan, Ph.D.⁽⁷⁾	30,827	*	—	—	*
Charles Li, Ph.D.⁽⁸⁾	31,683	*	—	—	*
Deborah Lafer Scher⁽⁹⁾	5,215	*	—	—	*
			—	—
*Named Executive Officers (other than those who are also directors)*			—	—
Jerome Wong⁽¹⁰⁾	27,455	*	—	—	*
Jason C. Jones⁽¹¹⁾	27,007	*	—	—	*

All current directors and executive officers as a group (7 persons)⁽¹²⁾	247,332	6.9%	—	—	5.8%
*Represents less than 1% of shares of common stock.

(1)	Based on information provided to the Company by Armistice Capital, LLC. Consists of 291,146 shares of common stock. Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the “Master Fund”), the direct holder of the common stock, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the common stock held by the Master Fund and thus may be deemed to beneficially own the common stock held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the common stock held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the common stock directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital. The address for Armistice Capital is 510 Madison Avenue, 7th Floor, New York, New York 10022.
(2)	Based on information provided to the Company by Cedar Holdings Mgmt LLC (“Cedar Holdings”). Consists of 210,000 shares of common stock held by Cedar Holdings. The address for Cedar Holdings is 100 S Pointe Dr Apt 2010, Miami Beach, FL 33139.
(3)	Based on information provided to the Company by Daniel Asher. Consists of (i) 165,000 shares of common stock held by Daniel Asher, (ii) 270,432 shares of common stock held by DBA Trading, LLC and (iii) 2,926 shares of Series B Preferred Stock being convertible and having the voting power of an aggregate of 355,961 shares of common stock held by the Daniel Asher Descendants Trust. Daniel Asher is the grantor of the Daniel Asher Descendants Trust and is deemed to control share voting and dispositive power over the shares held by them. Daniel Asher is the beneficial owner of, DBA Trading, LLC, and is deemed to control and share voting and dispositive power over the shares held by them. The address for Daniel Asher is 1011 Lake Street Suite 311 Oak Park, IL 60301.
(4)	Based on information provided to the Company by Hood River Capital Management LLC (“Hood River”). Consists of (i) 63,892 shares of common stock held by Hood River and (ii) 2,926 shares of Series B Preferred Stock held by Hood River being convertible and having the voting power of an aggregate of 355,961 shares of common stock. The address for Hood River is 2373 PGA Blvd., Suite 200, Palm Beach Gardens, FL 33410.
(5)	Consists of (i) 15,746 restricted stock units vesting within 60 days of the Determination Date and (ii) 14,701 shares of common stock.
(6)	Consists of 78,952 shares of common stock.
(7)	Consists of (i) 15,746 restricted stock units vesting within 60 days of the Determination Date and (ii) 15,081 shares of common stock.
(8)	Consists of (i) options to purchase 954 shares of common stock exercisable or exercisable within 60 days of the Determination Date (ii) 15,746 restricted stock units vesting within 60 days of the Determination Date and (iii) 14,983 shares of common stock.
(9)	Consists of (i) 15,746 restricted stock units vesting within 60 days of the Determination Date and (ii) 5,215 shares of common stock.
(10)	Consists of (i) options to purchase 355 shares of common stock exercisable or exercisable within 60 days of the Determination Date, and (ii) 27,100 shares of common stock.
(11)	Consists of (i) options to purchase 1,732 shares of common stock exercisable or exercisable within 60 days of the Determination Date, and (ii) 25,725 shares of common stock.
(12)	Consists of (i) 62,984 restricted stock units vesting within 60 days of the Determination Date (i) options to purchase 3,041 shares of common stock exercisable or exercisable within 60 days of the Determination Date, and (iii) 181,307 shares of common stock.

Plan category	(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights		(b) Weighted- average exercise price of outstanding options, warrants and rights		(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders		818,050	$	15.83		224
Equity compensation plans not approved by security holders		—	$	—		—
Total		818,050	$	15.83		224

	Year Ended December 31,
Description of Service	2025		2024
Audit Fees⁽¹⁾	$	756,457	$	727,433
Audit-Related Fees⁽²⁾		—		—
Tax Fees⁽³⁾		55,300		47,800
All Other Fees		2,100		—
Total Fees	$	813,857	$	775,233

	(1)	Audit Fees consist of fees for the audit of the Company’s annual financial statements for the respective year, reviews of the Company’s quarterly financial statements, services provided in connection with statutory and regulatory filings and the audit of the Company’s internal controls over financial reporting.
	(2)	Audit-Related Fees consist of fees for accounting consultations.
	(3)	Tax Fees consist of fees for tax compliance and tax advice and planning services.

Exhibit Number		Description

2.1#		Asset Purchase Agreement between the Registrant and Parker Hannifin Corporation, dated as of December 5, 2022 (incorporated by reference from Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed on December 5, 2022)

3.1		Restated Articles of Incorporation of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on April 26, 2023)

3.2		Amended and Restated By-Laws of the Registrant (incorporated by reference from Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on April 26, 2023)

3.3		Certificate of Designation of the Powers, Preferences and Relative, Participating, Optional and Other Restrictions of Series B Convertible Preferred Stock (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 22, 2026)

3.4		Amendment No. 1 to the Amended and Restated Bylaws of Ekso Bionics Holdings, Inc.

4.1		Form of specimen certificate (incorporated by reference from Exhibit 4.4 to the Registrant’s Registration Statement on Form S-3 filed on June 23, 2015)

4.2		Subordinated Promissory Note between Ekso Bionics Holdings, Inc. and Parker Hannifin Corporation, dated as of December 5, 2022 (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed December 5, 2022)

4.3*		Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

4.4		Form of Series A Warrant (incorporated by reference from Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed September 3, 2024)

4.5		Form of Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed March 17, 2025)

4.6		Form of Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on January 22, 2026)

4.7		Form of Placement Agent Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on October 30, 2025)

10.1		Form of Registration Rights Agreement (incorporated by reference from Exhibit 10.10 of the Registrant’s Current Report on Form 8-K filed on January 23, 2014)

10.2†		Amended and Restated 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 filed July 29, 2024)

10.3†		Amended and Restated 2014 Equity Incentive Plan Form of Phantom Performance-Based Restricted Stock Unit Agreement (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 7, 2025)

10.4†		Form of Director Option Agreement under 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.13 to the Registrant’s Current Report on Form 8-K filed on January 23, 2014)

10.5†		Form of Employee Option Agreement under 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.14 to the Registrant’s Current Report on Form 8-K filed on January 23, 2014)

10.6†		Form of Restricted Stock Unit Award under Amended and Restated 2014 Equity Incentive Plan (incorporated by reference from Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 filed July 29, 2024)

10.7†		2017 Employee Stock Purchase Plan (incorporated by reference from Appendix A to Registrant’s Proxy Statement on Schedule 14 filed on April 28, 2017)

10.8†		Scott Davis Offer Letter dated February 22, 2021 (incorporated by reference from Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed January 21, 2022)

10.9†#		Jason Jones Offer Letter dated January 2, 2023 (incorporated by reference from Exhibit 10.10 to the Registrant’s Annual Report on Form 10-K filed March 3, 2025)

10.10†		Jerome Wong Officer Offer letter, dated October 26, 2022 (incorporated by reference from Exhibit 10.11 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.11		Exclusive License Agreement, dated as of November 15, 2005, by and between The Regents of the University of California and Berkeley ExoTech, Inc., d/b/a Berkeley ExoWorks (incorporated by reference from Exhibit 10.19 to the Registrant’s Current Report on Form 8-K filed on January 23, 2014)

10.12		Exclusive License Agreement, dated as of July 14, 2008, by and between The Regents of the University of California and Berkeley ExoTech, Inc., d/b/a/ Berkeley Bionics and formerly d/b/a Berkeley ExoWorks (as amended by Amendment #1 to Exclusive License Agreement, dated as of May 20, 2009, by and between The Regents of the University of California and Berkeley Bionics) (incorporated by reference from Exhibit 10.20 to the Registrant’s Current Report on Form 8-K filed on January 23, 2014)

10.13		License Agreement between Vanderbilt University and Parker Hannifin Corporation, dated as of October 15, 2012 (as amended by the first amendment dated as of June 15, 2014, the second amendment dated as of December 1, 2018, and the third amendment dated as of May 1, 2019) (incorporated by reference from Exhibit 10.14 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.14		License Agreement between Vanderbilt University and Parker Hannifin Corporation dated as of March 1, 2022 (incorporated by reference from Exhibit 10.15 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.15		Vanderbilt Assignment and Assumption Agreement between Ekso Bionics Holdings, Inc and Parker Hannifin Corporation, dated as of December 5, 2022 (incorporated by reference from Exhibit 10.16 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.16†		Form of Non-Employee Director Indemnification Agreement (incorporated by reference from Exhibit 10.20 to the Registrant’s Quarterly Report on Form 10-Q filed on May 13, 2014)

10.17†		Form of Executive Officer Indemnification Agreement (incorporated by reference from Exhibit 10.21 to the Registrant’s Quarterly Report on Form 10-Q filed on May 13, 2014)

10.18		Lease, dated July 15, 2022, between Don Tornberg and Ekso Bionics Inc. (incorporated by reference from Exhibit 10.22 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.19		Transitional Use Agreement, dated December 5, 2022, between Parker Hannifin Corporation and Ekso Bionics Holdings, Inc. (incorporated by reference from Exhibit 10.23 to the Registrant's Annual Report on Form 10-K filed March 28, 2023)

10.20		Warranty Lump Sum Agreement between Parker Hannifin Corporation and the Company dated September 25, 2023 (incorporated by reference from Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q filed October 29, 2023)

10.21		Form of Inducement Agreement to Exercise Warrants (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed March 17, 2025)

10.22		Promissory Note and Security Agreement between Ekso Bionics Holdings, Inc. and B. Riley Commercial Capital, LLC, dated as of September 12, 2025 (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 17, 2025)

10.23#		Form of Securities Purchase Agreement (incorporated by reference from Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed on October 30, 2025)

10.24†		Change in Control and Severance Agreement, dated November 5, 2025, by and between the registrant and Scott G. Davis (incorporated by reference from Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on November 7, 2025)

10.25†		Change in Control and Severance Agreement, dated November 5, 2025, by and between the registrant and Jerome Wong (incorporated by reference from Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on November 7, 2025)

10.26†		Change in Control and Severance Agreement, dated November 5, 2025, by and between the registrant and Jason Jones (incorporated by reference from Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on November 7, 2025)

10.27		Placement Agency Agreement, dated October 28, 2025, by and between the Company and the Placement Agent (incorporated by reference from Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed on October 30, 2025)

10.28		Form of Registration Rights Agreement (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 22, 2026)

10.29#		Form of Securities Purchase Agreement (incorporated by reference from Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed on January 22, 2026)

10.30#*		Contribution and Exchange Agreement, dated February 15, 2026, by and among Ekso Bionics Holdings, Inc., APLD ChronoScale HoldCo LLC, APLD Intermediate HoldCo LLC, and Applied Digital Cloud Corporation

19.1		Ekso Bionics Holdings, Inc. Insider Trading Policy (incorporated by reference from Exhibit 19.1 to the Registrations Annual Report on Form 10-K filed on March 3, 2025)

21.1		Subsidiaries of the Registrant (incorporated by reference from Exhibit 21.1 to the Registrant's Annual Report on Form 10-K filed March 4, 2024)

23.1*		Consent of Independent Registered Public Accounting Firm (WithumSmith+Brown, PC)

24.1*		Power of attorney (included on signature page of the Original Filing)

31.1**		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

31.2**		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

32.1§		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2§		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.ins	Inline XBRL Instant Document
101.sch	Inline XBRL Taxonomy Schema Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

Signature	Title	Date

/S/ Scott G. Davis	Chief Executive Officer	April XX, 2026
Scott G. Davis	(Principal Executive Officer)

/S/ Jerome Wong	Chief Financial Officer	April XX, 2026
Jerome Wong	(Principal Accounting and Financial Officer)

*	Director	April XX, 2026
Mary Ann Cloyd

*	Director	April XX, 2026
Corinna Lathan, Ph.D.

*	Director	April XX, 2026
Charles Li, Ph.D.

*	Director	April XX, 2026
Deborah Lafer Scher


*By:	/s/ Scott G. Davis	April XX, 2026
	Scott G. Davis
	As attorney-in-fact

Amendment: SEC Form 10-K/A filed by Ekso Bionics Holdings Inc.